Hongyin Bio solves delivery pain points with milk-derived extracellular vesicles and seeks financing

Project Overview

Beijing Hongyin Biotechnology Co., Ltd. is promoting the "SYN-mEXO Milk-derived Exosome Reconstructed Peptide" project and seeking financing. This project targets the market for efficacy skincare raw materials. Aiming at issues such as insufficient delivery efficiency of active ingredients and the difficulty of core efficacy ingredients reaching the target action level effectively, it develops functional raw material solutions based on milk-derived exosomes.

Industry Pain Points: The Effective Utilization Rate of Efficacy Ingredients Needs to be Improved

In recent years, the efficacy skincare industry has been growing continuously. Areas such as anti-aging, repair, and collagen support have become key product fields for brand owners. As market competition intensifies, the focus of competition in efficacy skincare products is gradually shifting from ingredient addition to comprehensive competition in ingredient design, delivery systems, verification methods, and industrialization capabilities.

In the scenario of external skincare, the effective utilization rate of active ingredients has always been the core issue of industry concern. Although some efficacy ingredients have a clear research basis, they are affected by factors such as the skin barrier, molecular structure, stability, and formulation system, making it difficult to fully exert their effects in practical applications. For brand owners and OEM/ODM contract manufacturers, how to improve the stability, delivery efficiency, and application transformation ability of active ingredients has become an important requirement for the upgrade of efficacy products.

Solution: SYN-mEXO Milk-derived Exosome Reconstructed Peptide

Hongyin Biotechnology was established in Beijing in November 2024, focusing on the application of milk-derived exosome technology in the daily chemical and skincare field. The core idea of the "SYN-mEXO Milk-derived Exosome Reconstructed Peptide" project being developed by the company is to use milk-derived exosomes as a natural delivery structure and combine them with the SYN reconstructed peptide independently designed by the team to form a composite functional raw material for anti-aging and repair scenarios.

In terms of the technical route, the SYN-mEXO Milk-derived Exosome Reconstructed Peptide is mainly composed of two parts.

The first part is the mEXO milk-derived exosome. Milk-derived exosomes are derived from milk and belong to the natural vesicle structure at the nanometer level. They have a lipid bilayer, which is somewhat similar to the cell membrane structure. This type of structure has development potential in terms of active ingredient encapsulation, protection, stability, and biocompatibility, and is suitable for the research of delivery systems for external skincare raw materials. Its value lies in providing delivery support for efficacy ingredients and increasing the effective utilization opportunities of active ingredients in skin application scenarios.

The second part is the SYN reconstructed peptide. SYN is designed by the Hongyin Biotechnology team around the needs related to collagen production and is mainly used to support the development of anti-aging, repair, and collagen-related skincare products. Through a controllable encapsulation process, the project combines SYN with mEXO milk-derived exosomes to form the "SYN-mEXO Milk-derived Exosome Reconstructed Peptide" composite raw material. The design goal of this raw material is to improve the stability and delivery efficiency of functional ingredients in the scenario of external skincare applications and provide a new raw material solution for efficacy skincare brands.

Technical Judgment: From Ingredient Competition to Delivery and Verification Competition

According to Hongyin Biotechnology, the current efficacy skincare industry has entered a stage that attaches more importance to underlying technologies and verification logic. Brand owners' requirements for raw materials are extending from ingredient names and concept expressions to mechanisms of action, experimental verification, stable supply, and compliant delivery capabilities. Raw material enterprises need to provide not only single raw materials but also complete solutions that are explainable, verifiable, and applicable.

Verification Progress: Continuously Improving around Efficacy, Transdermal, and Application Tests

At the verification level, Hongyin Biotechnology has carried out work such as cell experiments, transdermal-related verifications, and human efficacy tests around the SYN-mEXO Milk-derived Exosome Reconstructed Peptide. The existing test results show that after continuous use, the relevant products have a positive improvement trend in skin indicators such as nasolabial folds, facial red areas, and acne red areas. The company is further improving the efficacy data, application tests, and factory inspection systems to support the product development needs of subsequent B2B customers.

Business Model: Targeting Brand Owners and OEM/ODM Customers

In terms of business model, Hongyin Biotechnology currently adopts the B2B model, mainly targeting mid - to high - end efficacy skincare brands, OEM/ODM contract manufacturers, raw material development enterprises, and product teams with efficacy upgrade needs. The company can currently provide the SYN-mEXO Milk-derived Exosome Reconstructed Peptide composite raw material, ultra-purified milk-derived exosome raw material, and related application solutions.

For brand owners, this technology platform can be used to improve the differentiated expression and R & D verification capabilities of efficacy products; for OEM/ODM contract manufacturers, a technology platform with differentiated raw materials and complete application solutions helps to improve their product development capabilities and customer service capabilities.

Current Progress: R & D, Samples, and Verification Foundations Completed

Currently, Hongyin Biotechnology has completed the R & D of the core platform, the preparation of raw material samples, third - party efficacy verification, and the layout of relevant intellectual property rights. The project has released its technology at the PCHI industry summit and has started to enter the stage of docking with brand owners and OEM/ODM customers. At the same time, the company has established a joint laboratory for daily chemical applications in the Zhongguancun Comprehensive Bonded Area in Beijing for subsequent R & D, small - scale preparation, and application tests.

Team Background: Promoting Industrialization through Industry - University - Research Collaboration

In terms of the team, Li Ye with a background in film and television and business administration serves as the CEO, responsible for the company's strategic planning, financing, market expansion, and promotion of industrial cooperation. The R & D work is led by Dr. Li Pengtao from Peking Union Medical College Hospital and jointly promoted by scientific researchers with experience in extracellular vesicles, skin applications, and efficacy verification. The team hopes to promote the industrialization application of milk-derived exosome technology from laboratory research to daily chemical skincare raw materials through the combination of industry, university, and research.

Use of Financing: Verification, Production, and Market Expansion

After the completion of this round of financing, Hongyin Biotechnology plans to mainly use the funds in three aspects: first, to continue to improve the efficacy verification and application data of the SYN-mEXO Milk-derived Exosome Reconstructed Peptide; second, to improve the small - scale and medium - scale production capabilities and perfect the quality control and factory inspection systems; third, to accelerate the market expansion among brand owners, OEM/ODM contract manufacturers, and raw material channel customers.

Hongyin Biotechnology said that the efficacy skincare industry is entering a stage that attaches more importance to real efficacy and underlying technologies. The company hopes to help brand owners and contract manufacturers improve the application efficiency of efficacy raw materials based on the milk-derived exosome delivery system and promote Chinese original efficacy skincare raw materials to enter a more systematic and platform - based development stage.